Drug Makers Encounter Cultural Differences in Asia

Article

BANGKOK, Thailand-Makers of pharmaceuticals for the mentally ill were excited at the possibility of selling their products to more than 2 billion people in Asia.

What they didn't expect was the prevalence of shamans and fortune tellers treating such patients.

When Eli Lilly and Co. decided to research the Asian market in 1980, many doctors told them there was no mental illness in the region. Healthcare workers and the public had no knowledge of depression or schizophrenia, even though US researchers estimate Asians suffer from depression as frequently as Americans.

An estimated 3% of both populations are afflicted.

Doctors frequently reported patients coming to their hospitals for somatic complaints like pain, lack of sexual response, hyperventilation or paralysis of limbs. Physicians blamed these symptoms on their patient's lack of expressing their feelings.

However, American pharmaceutical companies, examining the possibly of treating the continent, have now invested millions of dollars into education programs for Asian healthcare workers and funded national public health campaigns.

Eli Lilly sponsors postgraduate research and courses for Asian doctors studying psychiatry. Johnson & Johnson brought US schizophrenia advocacy groups and Asian families with schizophrenic relatives together. Johnson & Johnson hosts seminars for psychiatrists to teach them about treating the mentally ill.

Even though many of these doctors agree that Western medication could help the Asian population, they understand that educating the public about a problem they don't believe to exist, will not be easy.

Information from The Wall Street Journal.

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
 Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
 Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
In a recent discussion with Infection Control Today® (ICT®), study authors Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio, shared their insights on how the project evolved and what the findings mean for the future.